Let us explore the potential of ivermectin, an antiparasitic drug, as a cancer treatment. One source reviews preclinical studies demonstrating ivermectin's ability to inhibit cancer cell growth through various mechanisms, including inducing programmed cell death and targeting multiple signalling pathways. Another source presents a study on ivermectin's use as an alternative cancer therapy in a specific region of Ecuador, highlighting its popularity among some patients despite a lack of scientific evidence supporting its efficacy and medical professionals' lack of endorsement. A third source details preclinical research showing that ivermectin synergistically enhances the effects of immune checkpoint inhibitors in treating breast cancer, promoting tumour regression and inducing protective immunity, which is promising for future clinical applications.